These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11738121)

  • 1. Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods.
    Journot V; Chêne G; Joly P; Savès M; Jacqmin-Gadda H; Molina JM; Salamon R;
    Control Clin Trials; 2001 Dec; 22(6):639-58. PubMed ID: 11738121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children.
    Palumbo PE; Raskino C; Fiscus S; Pahwa S; Fowler MG; Spector SA; Englund JA; Baker CJ
    JAMA; 1998 Mar; 279(10):756-61. PubMed ID: 9508151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics.
    Le Corfec E; Chevret S; Costagliola D
    Stat Med; 1999 Jul; 18(14):1803-17; discussion 1819. PubMed ID: 10407251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
    Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*.
    Stephan C; Hill A; Sawyer W; van Delft Y; Moecklinghoff C
    HIV Med; 2013 May; 14(5):284-92. PubMed ID: 23171153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
    Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
    J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
    Cohen CJ; Hunt S; Sension M; Farthing C; Conant M; Jacobson S; Nadler J; Verbiest W; Hertogs K; Ames M; Rinehart AR; Graham NM;
    AIDS; 2002 Mar; 16(4):579-88. PubMed ID: 11873001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
    Yozviak JL; Doerfler RE; Woodward WC
    Clin Infect Dis; 2002 Feb; 34(4):547-50. PubMed ID: 11797185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy.
    Medeiros RP; Munerato P; Diaz RS
    J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
    Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
    JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.
    Raffi F; Bonnet B; Ferré V; Esnault JL; Perré P; Reliquet V; Leautez S; Bouillant C; Vergnoux O; Weinbreck P
    Clin Infect Dis; 2000 Nov; 31(5):1274-8. PubMed ID: 11073763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.